Zi Yang Shi

Researchers are evaluating the safety and effectiveness of inhaled Peginterferon alpha-2b at two different doses combined with supportive care for children aged 1 to 6 years who have common hand, foot, and mouth disease HFMD. This multicenter clinical trial aims to better understand treatment options for this illness by comparing two dose levels of the medicine delivered by nebulization. The study is sponsored by Zhengzhou Childrens Hospital in China and plans to enroll 90 participants. Participants will be randomly assigned to one of two groups receiving either 45 mcg or 90 mcg doses of nebulized Peginterferon alpha-2b on Day 1 and Day 3, alongside standard supportive care. The study includes a 3-day screening period followed by a 5-7 day inpatient treatment phase during which the investigational treatments are administered. The trial focuses on monitoring responses to these treatments while participants remain hospitalized. During participation, children will be closely monitored for the resolution of fever, skin rash, oral ulcers, and feeding difficulties over the first week. Researchers will collect data on the time it takes for these symptoms to improve or resolve. They will also assess safety by tracking any serious complications such as pulmonary edema or myocarditis. The total participation involves screening, inpatient observation, and follow-up to measure treatment outcomes and safety.

Researchers are evaluating the safety and effectiveness of low-dose tenecteplase in elderly patients aged 70 and older who have experienced an acute ischemic stroke. This multicenter, randomized controlled trial focuses on treatment within 4.5 hours of stroke onset to assess how this therapy may improve neurological outcomes compared to a standard dose. Participants are randomly assigned to receive either a low dose 0.175 mgkg, up to 17.5 mg or a standard dose 0.25 mgkg, up to 25 mg of tenecteplase given intravenously. The study is designed as a parallel-group trial comparing these two dosing regimens to understand which may be more beneficial and safe for elderly stroke patients. Participants will be monitored for recovery and safety through neurological assessments using scales such as the Modified Rankin Scale and the National Institutes of Health Stroke Scale up to 90 days after treatment. Outcomes like neurological improvement, functional independence, quality of life, and any bleeding events will be closely measured. The trial will continue until December 2028, with follow-up visits planned to evaluate participants progress and overall health.